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This article provides a comparison of psychopharmacological practices in
the u.s .and France. T he prescription as well as proscription of variou s classes of
psychotropic drugs are considered. Even though the general guidelines of
psychopharmacological practice remain the same, the detail s vary co nsiderably
and are determined especially by commercial factors.
INTRODUCTION
Though a comparison of current clinical psychopharmacologica l practi ces
in France and the u.s. is an unaddressed topic, these co ntrasts may be quite
striking to an American-trained psychiatrist. The following observations are
based on my two month inpatient experience as a fourth-year psych iatr ic
resident at a public psychiatric institution located in Montpelli er, Fran ce (1987).
This article was written in collaboration with Dr. Blayac who is one of th e
regional center directors for the Fr ench equivalent of th e FD A.
Before I begin to discu ss this topic, I think th at th e reader should be made
aware of some fundam ental differences between French and American psychi a-
try. Fren ch psychiatry is an integral part of a socialized for m of med icine, whi ch
helps one understand th e socioeconomic setting in whi ch French psych opharma-
cology is practiced as well as these practices' financial co ns tra in ts. This may a lso
contr ibute to the practical pharmacological orientation one observes in a public
setting, even where a psychodynamic orientation is very often th eoret ica lly
proposed. An additional difference is that the Fr ench public sec to r combines
academic and community psychiatry synonymous ly. This does not appear to
ha ve much bearing on psychopharmacol ogi cal practi ce.
T h is a r ticle intends to aler t th e reader to a different sp here of psych ophar-
ma cological practi ces wh ich may help th e Amer ica n cli nician reassess what
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he/she is doing presently in this country . Let me simply state that none of the
following different practices are absolutely or uniforml y foll owed in France but
th at the ba sic tendencies and mode of practice are co nsis tent with what is
currently considered acceptable in French psychiatry.
Therefore, in order to better understand the differences (Table 1) between
psychopharmacological practices in France and th e U .S., I will firs t consider
their similarities.
SIMILARITIES
The similarities between the U.S. and France with respect to psych ophar ma-
cologica l practice reflect certain general universal guideli nes of treatment.
Antipsychotics are primarily indicated for psychoses. Lithium therapy is the first
line drug in the prophylactic treatment of bipolar disorder. Antidepressants
including polycyclic antidepressants and MAO inhibitors a re indicat ed for major
depression and relatively contraindicated in psychotic and bipolar di sorders (1).
Antianxiety agents including benzodiazepines, antihistamines, propaned iols and
barbiturates, are used to treat anxiety and sleep disorders.
DIFFERENCES
Neuroleptic Treatment
In the United States, one can say that it is a fairl y common practice to place
an acutely psychotic individual on one neuroleptic at a time (2), wh ose reason-
abl e trial extends to a minimum of two or more weeks depend ing on the severity
TABLE 1.
Major Differences
# of Neuroleptics used at
one time
Lithium Alternatives
Commercialized and com-
monly used antichol-
linergic
Antidepressants
1M Benzodiazepines
US
I
Carbamazepine
Benztropine
Trihexyphenidyl
TCA
MAO!
Lorazepam
France
2:2
Valpromide
Biperiden
Trihexyph en idyl (both
are pip eridine deri va-
tives)
TCA with am phetamine
like propert ies:
Ami ne ptine
MAO I- A selective:
Toloxato ne
Diazep am
Clorazepate
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TABLE 2.
Neuroleptics
5
Number
Type
1M Decanoates
1M Short Acting
Not commercialized in
corresponding country
us
I
High, Intermediate or low
potency
Haloperidol 50- 100 mg q
4 wks
Fluphenazine 12.5-50 mg
q 2 wks
Droperidol as Preanaes-
thetic 2.5 to 10 mg
IM/inj
Substituted Benzamides
(except Metodopra-
mide)
Carpipramine
FRANCE
~2
High and Low poten cy
(high dose) (low dose)
Haloper idol 100- 300 mg
4 wks
Fluphenazine 25-
100 mg/ 3 wks
Pipoti azine
M2 form 25-
100 mg/ 2 wks
L4 form 25 -
100 mg /4 wks
Perph en azine 100 mg q 2
wks
Flupentixol 40 mg q 2 wks
Drop er idol as antipsy-
chotic 25-50 mg
IM/inj
Cloza pine
of impairment (2) . Mo st recently, benzodiazepines with short half-lives (i.e.
Lorazepam) are sometimes combined with neuroleptics during initia l tr eatment
(3,4). It should be noted at this point that in th e United Stat es co nsideration of
possible late onset tardive dyskinesia is commonly present in th e clinician's mind
when he prescribes neuroleptics, in part because of its forensic co nsequences (5).
On inpatient psychiatric units in France , it is quite co mmon to treat
schizophrenic patients concomitantly with two neuroleptics; th ere is usua lly one
high potency neuroleptic such as Haloperidol, at doses ranging from 30 to 40 mg
per day, combined with relatively lower doses (under 150 mg per day) of a low
potency neuroleptic such as chlorpromazine (6). T he sedating low potency
neuroleptic is used for its tranquilizing effect. T ardive dyskinesia is a consider-
ation; however, the legal implications are not a determinant or a det errent in the
evaluation of the medication's risks. T he rationale for combining the two
different classes of neuroleptics are the following:
a) Historically this mode of prescription dates back many years and is
co nsidered fairly conventional by both psychopharmacologists and clinical prac-
titioners, although this association was studied in th e 1960's and considered by
many American authors such as Freeman (7) to be no more effective than
monotherapy throughout the treatment 's duration.
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b) The anticholinergic effects of the low-potency neurol eptic decreases the
extr apyramida l side effects ofthe high-potency neuroleptic. The result is thought
to produce a decreased ins tance of secondary side effect s (8); o ther anticholin-
ergic medica tions are, therefore, less necessary. This does not imp ly, however ,
that one never sees anticholinergic medications prescribed in association with
high-potency neuroleptics. The latter brings us to the co nt inuing debate over
whether or no t to combine antichol inergic medications with high-po te ncy
neuroleptics for prophylaxis of extrapyramidal side effects. This debate is ac tive
on both sides of the Atlantic (2 ,6). Here, le t me note that sim ilar an tich o linergic
medica tions exist in bo th countries, but prescribing patterns differ (Table 1).
For example, benztrop ine is rarely used in France; while biperiden , wh ich has a
shorter halfl ife is co mmonly used in France, in both oral and depot forms (9, 10).
T he ultimate effec t is the same but the choice of drug is com mon ly based more
on com merc ia l factors .
A nother important note that must be made concerning the treatment of
other side-effec ts secondary to neuroleptics, refers to orthostatic hypotension .
In Fran ce this is syste matica lly treate d by a sym pathomimetic drug known as
heptaminol (6) . Phenylephri ne , presents this ind ication in France but is not used
fo r th is purpose in curren t common U .S. cli nica l psychiatric inpatient practi ce .
In the U .S. , patients are first advised to r ise slow ly from a sitting positi o n;
support hose o r stockings are a lso so metimes suggested. Often the drug may be
discontinued . IV in fusio n of a vasopressor agent, such as norepinephrine , may
be recom mended theoretically only in severe cases (2), given that postu ral
hypote nsion usuall y occurs only during the first few days of treatment a nd is not
ord inarily troublesome when the dose is given orally.
In the Uni te d States the depot forms of neuroleptics are commonly used .
T he fluphenazine decanoa te dosage usually ranges from 25 mg to 50 mg 1M
every two weeks. Most recently, haloper ido l deca noate ha s been mark eted in this
country and the initial maximum dose is 100 mg 1M every four weeks.
In France, depo t neuroleptics have bee n used for many yea rs. No t only do
they have haloperid ol and fluphenazine in this pharmaceutical preparati on but
they a lso use depo t fo r ms of other piperazine or piperidine phenothiazines
(p ipotiaz ine and perphenazine) as we ll as the depot form of the thi ox anthine
flupentixol (11). Hi gher doses of decanoat e are usually prescribed, such as 100
to 300 mg 1M of haloperidol decan oate every fo ur weeks, and 25- 100 mg 1M of
fluph enazine decanoate every three weeks. Interestingly, decanoates are a lso
indicate d in lower doses for adolescent co nduct d isorders. I noted this clini cal
psychopharmacological pract ice wh ile wor king in France; I was not, however ,
ab le to find j us tification for this p ractice in any of the literature. The ra t iona le
given behind th is indication was that many of these adolescents are consid ered
laten t schizophrenics . Given the ir poor compliance with medication s as well as
the need for behavioral co ntrol of this anger prone population , th e use of
low-dose depot neuroleptics is thought to be quite helpful therapeut icall y for
these patients. It is par ticula rl y interesting to note that in th e Unite d States,
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these sa me adolescents would most likely be given a tria l of a tricyclic antidepres-
sant.
In France, the frequent use of the butyrophenone d roperidol for prompt
control of psychotic agitation (6) is also notable, though in the United States it is
used only as a pre-anesthetic medication (10). The doses used in the United
States are lower (10) than those used in France . In practice , it is administered
intramuscularly. Theoretically it may be given intravenously.
Finally, and most importantly, it shou ld be noted that th ere exists in France
an entire cla ss of neuroleptics, call ed substitu te d benzamides (I I ). Metoclopra-
mide is the only subs titu ted benzamide available in th e U nited States however ,
and is approved only for treatment of gastrointestinal di sorde rs (10). Su lpiride
and su ltopride, which have existed for many yea rs in Europe, are no t available in
the United States. The rea son given for the non-approval of th ese drugs is th at
there is concer n about long term toxicity, that they increa se p rolactin secretion
to a higher degree than classical neuroleptics and that th ei r superior antipsy-
chotic effect is debatable. The literature has shown that th ese agents are
effective antipsychotic drugs (12 , I 3). It is significan t that in France bromocrip-
tin e is sometimes associated with sulpi ride as a prophylaxis against galactorrhea
(5), just as benztropine is associated prophylacti call y with haloper ido l in the
event of extrapy ramida l side effects. Carpipramine represents another class of
antipsychotic wh ich has been com mercialized in Fran ce since 197 7 (14); it has
antidepressant properties like su lp iri de (6).
Lithium Therapy
There are not too many French/U .S. differences concern ing th e use and
indications for lithium therapy. French clinicians are reluct ant to use lith ium for
an ything other than its primary indication of bipolar dis o rder. Becau se of the
required biological su r veillances, the latter is especially tr ue in the public sector
where compliance is questionable , and financial cost a considera tion. As for
alternat e treatments, it can be no ted that carbamazepine trials are rather recent
in Fran ce (five yea rs) . Howe ver , valprom ide, which is chemically related to
va lpro ic ac id, has been formall y recognized and co m merc ia lized in France since
197 I (14) as an alternate when lithium is co ntraind ica te d (I 1,1 5).
Antidepressants
MAO inhibitors are seldom prescribed in France (16) . There are several
exp lana tio ns for thei r proscriptio n. Wine and cheese are an integral part of all
meals in France which mak es the use of MAOI 's rather difficu lt even though it is
recognized th at o nly 20 % or less of pat ients may develop a hypertensive crisis on
a tyr amine-containing di et. However , the main reaso n for the proscription of
th ese drugs is that psychiatrists are ser io us ly di scouraged by anesthesiologists to
p rescribe th em, because of thei r contraind ica t ion with d r ugs such as meperi-
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dine. There are no litigation issues involved here. Phenel zine su lfate was
removed from the French commercial market in the 1970's because of insuffi-
cient use by practitioners. Tranylcypromine is still commerciali zed in Fra nce but
very rarely prescribed. There is, however, a new MAO inhibitor, toloxatone ,
which has appeared on the French market in the past six yea rs and is prescribed
because of its selective MAO I-A activity (11). Toloxatone , ha s only slight and
reversible tyramine potentiating effects and therefore, does not present the
absolute restrictions associated with conventional MAO inhibi tors.
Polycyclic Antidepressants As noted earlier, polycyclic antidepressants in
France are characteristically used for major depression ; howe ve r , there are
certain differences that should be considered. First of all , benzodiazepi nes are
quite often combined with antidepressants during the first two weeks of therapy
(16). The rationale for this combination rests on th e conclus ion th a t h igh levels
of anxiety during the first two weeks of treatment may contribute to suicide .
Second, an interesting practice on French inpatient units is to adm in iste r
antidepressants intravenously (16). The rationale behind this practice is the
following: 1) IV infusions decrease the risk of suicide, as th e pati ent is not free to
move about and leave the unit; 2) Having an IV infusion or a heparin lock has a
placebo effect ; 3) Pharmacologically, the therapeutic levels are ac hieved more
rapidly, though the one to three week delay in antidepressant response is not
shortened in these cases.
Third, the potentiation of the therapeutic effect of a tricyclic ant idepressant
by the addition of a thyroid hormone is not a common practi ce o n French
inpatient units, even though they recognize that it increases th e blood level of
the TCA (17) . On the other hand, the addition of tryptophan to a tricyclic
antidepressant is practiced (16); however, the doses of tryptophan are ten times
smaller than recommendations given in British literature (18, 19).
Another association with a TCA concerns one of its anticholinergic side
effects. Orally administered anetholtrithione com mercia lized as sulfa rlem S 25
(14), is commonly used in France to treat dry mouth secondary to a TCA,
MAOI, neuroleptic or other anticholinergic medications. In th e U.S., loca lly
applied pilocarpine is theoretically recommended (2) . H owever , it is not com-
monly used, given its transitory relief, the patient's eventual tolerance , and the
temporary nature of the autonomic side effects during early stages of trea tm ent
(2). Conversely, a product such as bethanechol, which is recommended for
urinary hesitation in the U .S. (20), does not exist in Fran ce. According to
Lambert (16), urinary hesitation is related to the dose of th e drug or underlying
prostatic hyperthrophy, and implies that these two factors are th e o nes which
should be modified or treated to relieve the patient 's discomfort.
Fourth , there does exist an antidepressant commerciali zed in France that
has amphetamine-like properties, amineptine (14), whi ch is very co m monly used
in major depression with psychomotor retardation. Amineptine di ffers from
conventional cyclic antidepressants in its dopaminergic ac t io n (it can be
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hypothesized that sulpiride in lower doses also act s as an antidepressant by th is
same mechanism of action) (21). Amineptine has been comme rcial ized in Fran ce
since 1978 (14). The addition of amphetamine like drugs such as methylphen i-
dat e has been recognized in th e U .S. as an adjunct in the treat ment of refractory
depression (2 1,22 ,23), as well as for treatment o f depression in the elderly. St ill
its e fficie ncy when used alone, is debated by certain authors (1,25, 26). An
interesting note is that methylphenidate was dropped from the Fre nch commer-
cial market because of its addictive properties (27), a nd replaced by other drugs
(fenety lline, fenozolone , prolintane) which are reportedly less effec tive th erapeu-
ticall y and have lesser sid e effects. The above perhaps e xp lains why a TCA is
more commonly used in France to treat attention defi cit di so rder with hyperac-
tivity in ch ild r en as opposed to stimulant drugs.
Finally, the TCA clomipramine has long been recognized as indicat ed in th e
treatment of obsessive compulsive disorder (commerciali zed in Fra nce since
1972) (14). It is commonly used for this disorder as well as affecti ve illn ess. It just
recently appeared on the U .S. market.
Antianxiety Agents
Benzodiazepines represent a class of drugs most fr equently prescr ibed in th e
U.S. and France (26); however, they are not controlled subs ta nces in France (I I )
as th ey are in the U.S.A. (requiring a DEA number). Furthermore , th e intram us-
cu lar form of short-acting benzodiazapines such as lorazepam are not available
com mercia lly in France; the latter is consistent with use of an 1M short acting
neuroleptic, such as droperidol , for acute agitation . T he only in tramuscular
benzodiazepines available com mercially in France ( I I) are diazepa m and clo-
ra zepate. Their clinical indications, including alcohol detox ificat ion , are th e
same as in the U .S.A. Meprobamat e is sti ll commonly used in France; one of its
primary indications is also alcohol detoxification (29).
CONCLUSION
The similarities reflect that the same general gu ide lines and r ules are
respected by both countries. However, clinical psychopharmacological practice
in the U.S . and France are quite different when one pays attention to its detail s.
The relative lack of forensic considerations in France is suc h that neuroleptics
are more widely and liberally used. The absence of legal cons trai n ts makes
polypharmacy a more prominent issue. The simultaneous use of two or more
neuroleptics, the common use of heptaminol for th e treatment of orthostatic
hypotension, the common use of anetholtrithione fo r the trea tment of dry
mouth a nd the use of bromocriptine for the treatment of secondary ga lactor-
r hea are all illu strations of French polypharmacy. Comme rcial factors are also at
play in determining the presence or absence of a pa rticul ar drug a nd , there fo re ,
its use in common clinical psych opharmacological practi ce in the respective
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country, making this an issue in both France and the U.S . It is in this ligh t tha t we
may observe the absence of the fo llowing drugs from the U .S. market: heptami-
nol, anetholtrithione, sulpiride and sultopride, carpipramine, toloxatone , aminep-
tine and valpromide to name a few. It is along this line of th ought that we note
th e absence of buspirone, bethanechol and clozapine from th e French market.
This paper does not address in any scientific or methodica l fashion the
comparative resu lt of the different clinical psychopharmacological practices that
I have outlined here . O ne wou ld hope that awareness of th e differen ces noted,
which this paper attempts to provide, will lead to further detailed invest igat ion
of the comparative results observed in both countr ies . One would th en hope that
clinical practice would benefit from such a comparison and exchange of ideas.
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